UBS Initiates Coverage On Solid Biosciences with Buy Rating, Announces Price Target of $20

UBS analyst Joon Lee has initiated coverage on Solid Biosciences (NASDAQ: SLDB) with a Buy rating. The firm has set a price target of $20 for the company's stock.